Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Bayer plc, 400 South Oak Way, Reading, RG2 6AD
Nimotop 0.02% Solution for Infusion.
| Pharmaceutical Form |
|---|
|
Clear yellow sterile solution for intravenous use. |
A sterile solution containing 10 mg nimodipine in 50 ml vials of aqueous alcoholic solvent (0.02%).
Excipients with known effect: Ethanol and sodium citrate.
For the full list of excipients see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Nimodipine |
Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels. |
| List of Excipients |
|---|
|
Nimodipine 0.02% solution contains the following excipients: Ethanol 96% |
Brown glass type II infusion vials containing 50 ml of solution; with grey chlorobutyl stopper laminated with fluoropolymer.
150 cm of colorless transparent polyethylene tubing with conus connector for each vial of 50 ml of Nimotop 0.02% Solution for Infusion.
Bayer plc, 400 South Oak Way, Reading, RG2 6AD
PL 00010/0138
21 January 1988/23 November 2003
| Drug | Countries | |
|---|---|---|
| NIMOTOP | Austria, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
